Drug Profile
APO 010
Alternative Names: APO-010Latest Information Update: 08 Sep 2023
Price :
$50
*
At a glance
- Originator Apoxis
- Developer Allarity Therapeutics; Valerio Therapeutics
- Class Antineoplastics; Recombinant fusion proteins; Tumour necrosis factors
- Mechanism of Action Apoptosis stimulants; CD95 antigen stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Multiple myeloma
- Discontinued Haematological malignancies; Solid tumours
Most Recent Events
- 22 Apr 2021 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in Switzerland (IV)
- 22 Apr 2021 Discontinued - Preclinical for Haematological malignancies in Switzerland (IV)
- 07 Oct 2020 Oncology Venture A/S is now called Allarity Therapeutics